A single dose of the GalNAc-siRNA, AB-729, results in prolonged reductions in HBsAg, HBcrAg, HBV DNA and HBV RNA in the absence of nucleos (t)ide analogue therapy in HBeAg negative subjects with chronic hepatitis B infection

被引：0

作者：

Gane, Edward ^{[1
]}

Sevinsky, Heather ^{[2
]}

Yuen, Man-Fung ^{[3
]}

Anderson, Mark ^{[4
]}

Cloherty, Gavin ^{[4
]}

Thi, Emily P. ^{[2
]}

Wattamwar, Tosh ^{[2
]}

Sofia, Michael J. ^{[2
]}

Gray, Kevin ^{[2
]}

Antoniello, Deana ^{[2
]}

Eley, Timothy ^{[2
]}

Picchio, Gaston ^{[2
]}

Sims, Karen ^{[2
]}

机构：

[1] Univ Auckland, Auckland, New Zealand

[2] Arbutus Biopharma, Warminster, PA USA

[3] Queen Mary Hosp, Hong Kong, Peoples R China

[4] Abbott Labs, Abbott Pk, IL 60064 USA

来源：

JOURNAL OF HEPATOLOGY | 2021年 / 75卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

PO-2879

引用

页码：S762 / S763

页数：2

共 16 条

[1] LOW HBsAg LEVELS MAINTAINED FOLLOWING CESSATION OF THE GALNAC-siRNA, AB-729, IN CHRONIC HEPATITIS B SUBJECTS ON NUCLEOS(T)IDE ANALOGUE THERAPY
Yuen, Man Fung
Berliba, Elina
Sukeepaisarnjaroen, Wattana
Tangkijvanich, Pisit
Leerapun, Apinya
Holmes, Jacinta A.
Gane, Edward J.
Jucov, Alina
Thi, Emily P.
Sofia, Michael J.
Sevinsky, Heather
Eley, Timothy
Medvedeva, Elina
Gray, Kevin
Antoniello, Deana
Picchio, Gaston R.
Sims, Karen
Strasser, Simone I.
HEPATOLOGY, 2021, 74 (06) : 1402A - 1403A
[2] Repeat dosing of the GalNAc-siRNA AB-729 in subjects with chronic hepatitis B results in robust and sustained HBsAg suppression
Yuen, Man-Fung
Berliba, Elina
Sukeepaisarnjaroen, Wattana
Strasser, Simone
Tangkijvanich, Pisit
Holmes, Jacinta
Leerapun, Apinya
Jucov, Alina
Thi, Emily P.
Wattamwar, Tosh
Sofia, Michael J.
Sevinsky, Heather
Gray, Kevin
Antoniello, Deana
Eley, Timothy
Picchio, Gaston
Sims, Karen
Gane, Edward
JOURNAL OF HEPATOLOGY, 2021, 75 : S203 - S204
[3] A COMPARATIVE ANALYSIS OF THE HBV RNA AND QUANTITATIVE HBSAG KINETICS BETWEEN HBEAG(+) AND HBEAG(-) PATIENTS WITH CHRONIC HEPATITIS B ON PROLONGED NUCLEOS(T)IDE ANALOGUES (NA).
Shah, Pir A.
Ishtiaq, Rizwan
Kaur, Satinder P.
Gersch, Jeffrey
Choudhry, Saad
Kuhns, Mary
Cloherty, Gavin A.
Lau, Daryl
GASTROENTEROLOGY, 2020, 158 (06) : S1315 - S1315
[4] Serum HBV RNA levels after nucleos(t)ide analogue therapy withdrawal in HBeAg negative patients with chronic hepatitis B: results from the Toronto STOP Study
Liem, Kin Seng
van Boemmel, Florian
Farag, Mina S.
Fung, Scott K.
Wong, David K. H.
Yim, Colina K.
Chen, Jiayun
Rother, Karen
Berg, Thomas
Feld, Jordan J.
Hansen, Bettina E.
Janssen, Harry L. A.
HEPATOLOGY, 2019, 70 : 614A - 614A
[5] EARLY ON-TREATMENT HBV RNA AND HBCRAG PROFILES PREDICT FAVOURABLE HBsAg SUPPRESSION OR SEROCLEARANCE UPON LONG-TERM NUCLEOS(T)IDE ANALOGUE THERAPY IN CHRONIC HEPATITIS B INFECTION
Mak, Lung-Yi
Wong, Danny
Kuchta, Alison
Hilfiker, Martina
Hamilton, Aaron
Seto, Wai Kay Walter
Yuen, Man-Fung
HEPATOLOGY, 2021, 74 : 433A - 434A
[6] BASELINE NUCLEOTIDE POLYMORPHISMS WITHIN HBV TARGET SITE IN CHRONIC HEPATITIS B SUBJECTS DO NOT IMPACT HBsAg REDUCTIONS MEDIATED BY RNA INTERFERENCE THERAPEUTIC AB-729
Espiritu, Christine
Steuer, Holly M. Micolochick
Ardzinski, Andrzej
Sharma, Varun
Eley, Timothy
Sims, Karen
Lee, Amy C. H.
Rijnbrand, Rene
Cuconati, Andrea
Mani, Nagraj
Lam, Angela M.
Sofia, Michael J.
Thi, Emily P.
HEPATOLOGY, 2023, 78 : S560 - S560
[7] HBV DNA AND HBsAg LOSS WITH BEPIROVIRSEN MONOTHERAPY IN PATIENTS WITH CHRONIC HEPATITIS B INFECTION NOT ON NUCLEOS(T)IDE ANALOGUE THERAPY: B-CLEAR STUDY END-OF-STUDY RESULTS
Lim, Seng Gee
Yuen, Man-Fung
Pojoga, Cristina
Janssen, Harry L.
Plesniak, Robert
Tsuji, Keiji
Janczewska, Ewa
Popescu, Corneliu Petru
Andreone, Pietro
Hou, Jinlin
Arbune, Manuela
Stefanova-Petrova, Diana
Inoue, Jun
Piratvisuth, Teerha
Lim, Young-Suk
Leerapun, Apinya
Atsukawa, Masanori
Jia, Jidong
Labio, Madalinee Eternity
Cremer, Jennifer
Elston, Robert
Lukic, Tamara
Quinn, Geoffrey
Kendrick, Stuart
Plein, Helene
Campbell, Fiona
Paff, Melanie
Theodore, Dickens
HEPATOLOGY, 2023, 77 (05) : E136 - E137
[8] HEPATITIS B VIRAL CONTROL MAINTAINED DURING EXTENDED FOLLOW UP OF HBEAG- CHRONIC HEPATITIS B (CHB) SUBJECTS WHO DISCONTINUED NUCLEOS(T)IDE ANALOGUE (NA) THERAPY AFTER COMPLETION OF AB-729 TREATMENT, AND IN HBEAG plus SUBJECTS STILL ON NA THERAPY
Yuen, Man-Fung
Holmes, Jacinta A.
Strasser, Simone I.
Leerapun, Apinya
Sukeepaisarnjaroen, Wattana
Tangkijvanich, Pisit
Sharma, Varun
Medvedeva, Elina
Thi, Emily P.
Picchio, Gaston R.
Eley, Timothy
Sims, Karen
HEPATOLOGY, 2023, 77 (05) : E156 - E157
[9] BEPIROVIRSEN (BPV) IN PATIENTS WITH CHRONIC HEPATITIS B VIRUS (HBV) INFECTION CONTROLLED BY NUCLEOS(T)IDE ANALOGUE THERAPY: HBV DNA AND HBsAg LOSS 6 MONTHS AFTER END OF BPV TREATMENT (B-CLEAR STUDY)
Yuen, Man-Fung
Lim, Seng Gee
Plesniak, Robert
Tsuji, Keiji
Diaconescu, Gheorghe
Gadano, Adrian C.
Asselah, Tarik
Yim, Hyung-Joon
Heo, Jeong
Rizzardini, Giuliano
Janssen, Harry L.
Popescu, Corneliu Petru
Stefanova-Petrova, Diana
Wong, Alexander
Idriz, Nevin
Pojoga, Cristina
Tanaka, Yasuhito
Janczewska, Ewa
Cremer, Jennifer
Elston, Robert
Lukic, Tamara
Maynard, Lauren
Kendrick, Stuart
Bharania, Punam
Campbell, Fiona
Paff, Melanie
Theodore, Dickens
HEPATOLOGY, 2023, 77 (05) : E129 - E130
[10] Continued suppression of viral markers observed following discontinuation of nucleos (t)ide analogue therapy in chronic hepatitis B subjects with low hepatitis B surface antigen levels after 48 weeks of treatment with AB-729
Yuen, Man-Fung
Strasser, Simone
Sukeepaisarnjaroen, Wattana
Sharma, Varun
Antoniello, Deana
Medvedeva, Elina
Thi, Emily P.
Picchio, Gaston
Eley, Timothy
Sims, Karen
JOURNAL OF HEPATOLOGY, 2022, 77 : S878 - S879

← 1 2 →